상세 정보

underline
Metadata Downloads : dc(xml) or Excel
Cited 0 time in scopus ci

Title 

Arazyme suppresses hepatic steatosis and steatohepatitis in diet-induced non-alcoholic fatty liver disease-like mouse model

 

비알콜성 지방간 모델 마우스에서 아라자임의 지방간 및 지방간염 억제 효능

Authors 

Hua LiWonbeak YooHye-Mi ParkSoo Youn LimD H ShinSeokho KimHo Yong ParkTae Sook Jeong

Publisher 

MDPI AG

Issue Date 

2019

Citation 

International Journal of Molecular Sciences

Keywords 

arazymediet therapynon-alcoholic fatty liver diseaseSREBP-1steatohepatitissteatosis 1. Introduction Non-alcoholic fatty liver disease (NAFLD) comprises chronic conditions including steatosis, steatohepatitis, and cirrhosis [1]. Hepatic steatosis causes increased hepatic lipid contents that mainly accumulate as triglyceride (TG) fat. During hepatic lipid accumulation, sterol regulatory element-binding protein 1 (SREBP-1) and carbohydrate responsive element-binding protein (chREBP) play critical roles as transcription factors in the synthesis of fatty acids and TG. The steatotic condition can further develop into steatohepatitis by triggering inflammatory cytokine production [2]. Non-alcoholic steatohepatitis is characterized by recruited macrophage-related inflammation and hepatic collagen synthesis-related fibrosis. The progression of NAFLD is closely associated with glucose homeostasis, insulin resistance, and inflammation: Notably, the prevalence rate of NAFLD is higher in overweight/obese patients with type 2 diabetes [3]. Furthermore, hepatic steatosis is a Int. J.

Abstract 

Arazyme, a metalloprotease from the spider Nephila clavata, exerts hepatoprotective activity in CCL4-induced acute hepatic injury. This study investigated the hepatoprotective e ects in high-fat diet (HFD)-induced non-alcoholic fatty liver disease-like C57BL/6J mice. The mice were randomly divided into four groups (n = 10/group): the normal diet group, the HFD group, the arazyme group (HFD with 0.025% arazyme), and the milk thistle (MT) group (HFD with 0.1% MT). Dietary supplementation of arazyme for 13 weeks significantly lowered plasma triglyceride (TG) and non-esterified fatty acid levels. Suppression of HFD-induced hepatic steatosis in the arazyme group was caused by the reduced hepatic TG and total cholesterol (TC) contents. Arazyme supplementation decreased hepatic lipogenesis-related gene expression, sterol regulatory element-binding transcription protein 1 (Srebf1), fatty acid synthase (Fas), acetyl-CoA carboxylase 1 (Acc1), stearoyl-CoA desaturase-1 (Scd1), Scd2, glycerol-3-phosphate acyltransferase (Gpam), diacylglycerol O-acyltransferase 1 (Dgat1), and Dgat2. Arazyme directly reduced palmitic acid (PA)-induced TG accumulation in HepG2 cells. Arazyme suppressed macrophage infiltration and tumor necrosis factor (Tnfa), interleukin-1 (Il1b), and chemokine-ligand-2 (Ccl2) expression in the liver, and inhibited secretion of TNF and expression of inflammatory mediators, Tnfa, Il1b, Ccl2, Ccl3, Ccl4, and Ccl5, in PA-induced RAW264.7 cells. Arazyme e ectively protected hepatic steatosis and steatohepatitis by inhibiting SREBP-1-mediated lipid accumulation and macrophage-mediated inflammation.

URI 

https://doi.org/10.3390/ijms20092325

ISSN 

1422-0067

Appears in Collections

1. Journal Articles > Journal Articles

Registered Date

2019-07-10


There are no files associated with this item.
qrcode

FusionCharts.
DSpace Software Coptright(c) 2010 MIT and Hewleft-Packard  /  KRIBB-REPOSITORY ( Email:jakim@kribb.re.kr)